Generic Name |
CS-1008, imatinib or sunitinib | |
---|---|---|
IND |
CS-1008, STI-571 or SU11248 | |
Brand Name (US) |
Gleevec, Sutent | |
Manufacturer |
Daiichi Sankyo | |
Drug Type |
Tyrosine Kinase Inhibitor and Monoclonal antibody | |
Delivery |
Intravenous, Oral | |
Approval Status |
CS-0118 is in phase 2 trials. A trial testing this combination was withdrawn. | |
Indications |
||
Overall Strategy |
KIT Protein Based | |
Strategy |
Activate death receptors + Block KIT | |
Drug Category |
KIT/PDGFRA inhibitor + Death receptor activator |
CS-1008 is an IgG1 agonistic humanized monoclonal antibody targeting the human death receptor 5 (DR5). CS- 1008 triggers apoptosis after binding to DR5 resulting in death of targeted cells; it has demonstrated cytotoxic activity against DR5-positive human tumor cell lines in vitro, and in vivo it has shown significant anti-tumor activity against human tumor xenografts in nude mice.